Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Adaptimmune Therapeutics PLC (ADAP) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K/A Financial Statements and Exhibits  Interactive Data
Docs: "UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL"
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Quarterly results
08/01/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/10/2023 4 Menzel Garry E (Director) has filed a Form 4 on Adaptimmune Therapeutics PLC
Txns: Sold 47,702 shares @ $0.9108, valued at $43.4k
07/10/2023 SC 13G/A Matrix Capital Management Company, LP reports a 17.3% stake in Adaptimmune Therapeutics PLC
07/05/2023 4 Hegde Priti (Director) has filed a Form 4 on Adaptimmune Therapeutics PLC
Txns: Granted 226,464 options to buy @ $0
Granted 109,746 options to buy @ $0
Granted 152,376 options to buy @ $0
07/05/2023 4 Allen Andrew R (Director) has filed a Form 4 on Adaptimmune Therapeutics PLC
Txns: Granted 73,212 options to buy @ $0
Granted 56,868 options to buy @ $0
Granted 45,348 options to buy @ $0
Granted 109,746 options to buy @ $0
Granted 152,376 options to buy @ $0
07/05/2023 4 Menzel Garry E (Director) has filed a Form 4 on Adaptimmune Therapeutics PLC
Txns: Granted 736,548 options to buy @ $0
Granted 1,251,966 options to buy @ $0
Granted 359,700 options to buy @ $0
Granted 3,568,026 options to buy @ $0
Granted 57,846 options to buy @ $0
Granted 2,715,816 options to buy @ $0
Granted 2,158,776 options to buy @ $0
07/03/2023 4 Behbahani Ali (Director) has filed a Form 4 on Adaptimmune Therapeutics PLC
Txns: Granted 933,317 options to buy @ $0
07/03/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/03/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/03/2023 4 Menzel Garry E (Director) has filed a Form 4 on Adaptimmune Therapeutics PLC
Txns: Granted 981,463 options to buy @ $0
07/03/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/03/2023 4 Alleva Lawrence M (Director) has filed a Form 4 on Adaptimmune Therapeutics PLC
Txns: Granted 1,077,756 options to buy @ $0
07/03/2023 4 MOTT DAVID M (Director) has filed a Form 4 on Adaptimmune Therapeutics PLC
Txns: Granted 1,462,927 options to buy @ $0
07/03/2023 4 Allen Andrew R (Director) has filed a Form 4 on Adaptimmune Therapeutics PLC
Txns: Granted 500,000 options to buy @ $0
06/29/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
06/29/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
06/29/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "RULES of the ADAPTIMMUNE THERAPEUTICS PLC 2015 SHARE OPTION SCHEME Adopted by the Company on 16 March 2015 Amended on 15 April 2015, 13 January 2016, 18 December 2017 and 29 June 2023 CONTENTS 1. DEFINITIONS 3 2. ELIGIBILITY FOR EMI OPTIONS 9 3. GRANT OF OPTIONS 9 3a. SCHEME LIMIT 11 4. OPTION PRICE 13 5. VESTING SCHEDULE AND PERFORMANCE TARGETS 13 6. LIMITS 15 7. EXERCISE and Lapse OF OPTIONS 15 8. MANNER OF EXERCISE OF OPTIONS 18 9. TAX LIABILITIES 20 10. NON-TRANSFERABILITY OF OPTIONS 21 11. TAKEOVERS 21 12. QUALIFYING EXCHANGE OF SHARES 22 13. sale 22 14. listing 22 15. VARIATION OF SHARE CAPITAL 23 16. RELATIONSHIP WITH EMPLOYMENT CONTRACT 24 17. VARIATIONS AND TERMINATION 24 18. HMRC REQUESTS 25 19. EMI 25 20. GENERAL 25 21. GOVERNING LAW AND JURISDICTION 26 Page 2 RULES OF THE ADAPT...",
"RULES of the ADAPTIMMUNE THERAPEUTICS PLC 2016 EMPLOYEE SHARE OPTION SCHEME Adopted by the Company on 14 January 2016 and amended on 18 December 2017 and 29 June 2023 CONTENTS 1. DEFINITIONS 3 2. ELIGIBILITY FOR EMI OPTIONS 9 3. GRANT OF OPTIONS 9 3a. SCHEME LIMIT 12 4. OPTION PRICE 13 5. VESTING SCHEDULE AND PERFORMANCE TARGETS 13 6. LIMITS 14 7. EXERCISE and Lapse OF OPTIONS 15 8. MANNER OF EXERCISE OF OPTIONS 17 9. TAX LIABILITIES 19 10. NON-TRANSFERABILITY OF OPTIONS 21 11. TAKEOVERS 21 12. QUALIFYING EXCHANGE OF SHARES 21 13. sale 22 14. listing 22 15. VARIATION OF SHARE CAPITAL 22 16. RELATIONSHIP WITH EMPLOYMENT CONTRACT 23 17. VARIATIONS AND TERMINATION 23 18. HMRC REQUESTS 24 19. EMI 24 20. GENERAL 24 21. GOVERNING LAW AND JURISDICTION 25 Page 2 RULES OF THE ADAPTIMMUNE THERAPEUTI..."
06/01/2023 4 Menzel Garry E (Director) has filed a Form 4 on Adaptimmune Therapeutics PLC
Txns: Granted 200,646 shares @ $0
Granted 200,647 shares @ $0
Granted 209,931 shares @ $0
06/01/2023 3 Menzel Garry E (Director) has filed a Form 3 on Adaptimmune Therapeutics PLC
06/01/2023 3 Hegde Priti (Director) has filed a Form 3 on Adaptimmune Therapeutics PLC
06/01/2023 3 Allen Andrew R (Director) has filed a Form 3 on Adaptimmune Therapeutics PLC
06/01/2023 8-K Completion of Acquisition or Disposition of Assets, Departure of Directors or Certain Officers; Election of Directors; Appoin...
Docs: "CONFIDENTIAL",
"Letter of appointment The board of directors of Adaptimmune Therapeutics plc is pleased that you have agreed to join the Board as a non-executive director and to serve as a member of the Board's Remuneration Committee with effect from 1 June 2023. The terms of this letter will apply with effect from 1 June 2023. You will be based in, and perform your role as a non-executive, independent director and as a member of the Board's Remuneration Committee from [*]. This letter sets out the main terms of your appointment. If you need any more information, please let me know. By accepting this appointment, you agree that this letter is a contract for services and is not a contract of employment and you confirm that you are not subject to any restrictions which prevent you from holding office as a d...",
"Letter of appointment The board of directors of Adaptimmune Therapeutics plc is pleased that you have agreed to join the Board as a non-executive director and to serve as a member of the Board's Corporate Governance and Nominating Committee with effect from 1 June 2023. The terms of this letter will apply with effect from 1 June 2023. You will be based in, and perform your role as a non-executive, independent director and as a member of the Board's Corporate Governance and Nominating Committee from [*]. This letter sets out the main terms of your appointment. If you need any more information, please let me know. By accepting this appointment, you agree that this letter is a contract for services and is not a contract of employment and you confirm that you are not subject to any restriction...",
"Letter of appointment The board of directors of Adaptimmune Therapeutics plc is pleased that you have agreed to join the Board as a non-executive director and to serve as a member of the Board's Audit Committee with effect from 1 June 2023. The terms of this letter will apply with effect from 1 June 2023. You will be based in, and perform your role as a non-executive, independent director and as a member of the Board's Audit Committee from [*]. This letter sets out the main terms of your appointment. If you need any more information, please let me know. By accepting this appointment, you agree that this letter is a contract for services and is not a contract of employment and you confirm that you are not subject to any restrictions which prevent you from holding office as a director. 1. AP...",
"Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company First marketed engineered T-cell therapy for a solid tumor; BLA for afami-cel on track to complete submission in mid-2023 Compelling clinical data with late-stage programs targeting MAGE-A4 and mesothelin Preclinical programs targeting PRAME and CD70 in IND-enabling studies Adaptimmune funded into early 2026 with multiple value creating catalysts Webcast to be held tomorrow, June 2nd at 8 a.m. EDT: https://www.gowebcasting.com/12589"
05/30/2023 425 Form 425 - Prospectuses and communications, business combinations:
05/16/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/12/2023 8-K Quarterly results
04/21/2023 EFFECT Form EFFECT - Notice of Effectiveness:
04/20/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
04/18/2023 S-4/A Form S-4/A - Registration of securities, business combinations: [Amend]
04/05/2023 S-4 Form S-4 - Registration of securities, business combinations:
04/03/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/10/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy